1. Home
  2. MDGL vs BIO Comparison

MDGL vs BIO Comparison

Compare MDGL & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Madrigal Pharmaceuticals Inc.

MDGL

Madrigal Pharmaceuticals Inc.

HOLD

Current Price

$437.29

Market Cap

11.5B

Sector

Health Care

ML Signal

HOLD

Logo Bio-Rad Laboratories Inc.

BIO

Bio-Rad Laboratories Inc.

HOLD

Current Price

$367.90

Market Cap

10.1B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
MDGL
BIO
Founded
2011
1952
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
11.5B
10.1B
IPO Year
2005
1994

Fundamental Metrics

Financial Performance
Metric
MDGL
BIO
Price
$437.29
$367.90
Analyst Decision
Strong Buy
Hold
Analyst Count
19
3
Target Price
★ $685.78
$335.00
AVG Volume (30 Days)
★ 262.9K
221.8K
Earning Date
11-03-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 142.61
EPS
★ N/A
N/A
Revenue
$180,133,000.00
★ $2,583,200,000.00
Revenue This Year
$59.57
N/A
Revenue Next Year
$38.84
$2.13
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 0.65
52 Week Low
$393.61
$236.73
52 Week High
$615.00
$396.23

Technical Indicators

Market Signals
Indicator
MDGL
BIO
Relative Strength Index (RSI) 29.07 52.06
Support Level $416.21 $358.85
Resistance Level $546.29 $391.87
Average True Range (ATR) 18.02 12.10
MACD -1.58 -0.04
Stochastic Oscillator 1.57 49.59

Price Performance

Historical Comparison
MDGL
BIO

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.

About BIO Bio-Rad Laboratories Inc.

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Share on Social Networks: